NVO ($70.12) is trading below its intrinsic value of $124.62, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
NVO is poor value based on its earnings relative to its share price (23.7x), compared to the US market average (18.56x)
Valuation
NVO is good value based on its earnings relative to its share price (23.7x), compared to the US Biotechnology industry average (33.5x)
Valuation
1 of 13
NVO News
Valuation
NVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.7x
Industry
33.5x
Market
18.56x
NVO is poor value based on its earnings relative to its share price (23.7x), compared to the US market average (18.56x)
Valuation
NVO is good value based on its earnings relative to its share price (23.7x), compared to the US Biotechnology industry average (33.5x)
Valuation
NVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.93x
Industry
0x
Market
-0.01x
NVO is good value based on its book value relative to its share price (15.93x), compared to the US market average (-0.01x)
Valuation
NVO is good value based on its book value relative to its share price (15.93x), compared to the US Biotechnology industry average (0x)
Valuation
NVO price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVO is poor value relative to its rate of earnings growth, measured by PEG ratio (3.31x)
Valuation
NVO's financial health
Profit margin
Revenue
$6.1B
Net Income
$2.0B
Profit Margin
31.9%
NVO's Earnings (EBIT) of $9.14B can safely cover interest payments on company debt ($1.70B)
Financials
NVO's profit margin has increased (+1.3%) in the last year from (31.9%) to (33.2%)
Financials
Assets to liabilities
Assets
$23.8B
Liabilities
$13.4B
Debt to equity
0.16
NVO's short-term liabilities ($11.52B) exceed its short-term assets ($10.79B)
Financials
NVO's short-term assets ($10.79B) exceed its long-term liabilities ($1.86B)
Financials
NVO's debt has increased relative to shareholder equity (1.29), over the past 5 years ago (0.95)
Financials
NVO's debt to equity ratio (1.29) is considered high
Financials
Cash flow
Operating
$1.7B
Investing
-$2.3B
Financing
-$321.5M
NVO's operating cash flow ($8.52B) is sufficient to service the company's debt ($1.70B)
Financials
Novo Nordisk A S Stock FAQ
What is Novo Nordisk A S's quote symbol?
(NYSE: NVO) Novo Nordisk A S trades on the NYSE under the ticker symbol NVO. Novo Nordisk A S stock quotes can also be displayed as NYSE: NVO.
What is the 52 week high and low for Novo Nordisk A S (NYSE: NVO)?
(NYSE: NVO) Novo Nordisk A S's 52-week high was $75.86, and its 52-week low was $58.36. It is currently -7.57% from its 52-week high and 20.15% from its 52-week low.
How much is Novo Nordisk A S stock worth today?
(NYSE: NVO) Novo Nordisk A S currently has 2,357,900,000 outstanding shares. With Novo Nordisk A S stock trading at $70.12 per share, the total value of Novo Nordisk A S stock (market capitalization) is $165.34B.
Novo Nordisk A S stock was originally listed at a price of $2.89 in Dec 31, 1997. If you had invested in Novo Nordisk A S stock at $2.89, your return over the last 23 years would have been 2,330.5%, for an annualized return of 14.88%.
How much is Novo Nordisk A S's stock price per share?
(NYSE: NVO) Novo Nordisk A S stock price per share is $70.12 today (as of Apr 9, 2021).
What is Novo Nordisk A S's Market Cap?
(NYSE: NVO) Novo Nordisk A S's market cap is $165.34B, as of Apr 12, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Novo Nordisk A S's market cap is calculated by multiplying NVO's current stock price of $70.12 by NVO's total outstanding shares of 2,357,900,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.